Business Wire

Exscientia Business Update for First Quarter 2022


Exscientia plc (Nasdaq: EXAI)

This press release features multimedia. View the full release here:

Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform.

"We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we showed how a deep learning approach to phenomics can be integrated with single cell sequencing to potentially identify patient signatures and biomarkers in early discovery to stratify which treatment is likely to work best for each patient. With these advancements in our precision medicine platform, we are able to leverage AI to design and discover a new generation of medicines,” said Andrew Hopkins, DPhil., Exscientia's founder and Chief Executive Officer. "We are well-capitalised and are continuing to build an organisation with a balanced business model. This will enable us to continue advancing new medicine programmes, focusing on those areas where our platform and expertise provides the highest probability of success."

Recent Highlights

Recent progress demonstrates the Company’s patient tissue-derived translational capabilities, including identifying novel targets, evaluating modulation of complex tumour microenvironments, and enabling patient selection through biomarkers

- Exscientia researchers presented three posters at the AACR Annual Meeting in April:

  • Enriching for adenosine antagonist patient responses through deep learning: in this study, researchers modelled and functionally evaluated patient gene signatures to map the association of anti-cancer immune activity with the inhibition of adenosine signalling by EXS-21546, Exscientia's clinical stage A2a antagonist. These data suggest stratification of gene signatures could be used in future clinical studies to identify patients that may best respond to A2aR targeted therapies.
  • AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7: preclinical data highlighting potential benefits of Exscientia’s AI-driven design to overcome identified issues with CDK7 inhibitors, including toxicity and selectivity. In addition, the precision medicine platform identified patient subsegments that can inform biomarker strategies.
  • Deep learning supported high content analysis of primary patient samples identifies ALK inhibition as a novel mechanism of action in a subset of ovarian cancers: research highlighting the potential of Exscientia's precision medicine platform to identify novel targets and targetable pathways using human disease-relevant patient tissue models, which could have the potential to improve patient outcomes by uncovering clinical relevance at the target discovery stage.

- Together with the University of Oxford, the Company launched Xcellomics™, a programme that invites academic researchers to collaborate to advance novel phenotypic biology research with the potential to be developed into meaningful new therapies.

Continued to identify and validate new targets, as well as progress and prioritise broad pipeline

- Partnered programmes

  • Extended collaboration with Bristol Myers Squibb (BMS) to generate additional data including the use of precision medicine capabilities for key targets under the collaboration; $5 million in cash inflows in first quarter 2022 to be recognised as revenue throughout 2022
  • Target identification and validation ongoing in Sanofi collaboration, signed in January 2022, leveraging precision medicine platform and Centaur Biologist

- Co-owned programmes

  • GTAEXS-617 CTA submission expected by year-end 2022, progress in generating data in additional tumour types to inform planned Phase I clinical trial in cancer patients
    • CTA and IND-enabling studies are ongoing, including pre-clinical studies to explore potential dosing regimens for planned clinical trials

- Wholly and majority owned programmes

  • EXS-21546 top-line data for Phase 1 healthy volunteer study on track for the first half of 2022
    • Anticipate commencing Phase 1b/2 study in patients with high adenosine signature cancers in the second half of 2022

Strong balance sheet and anticipated cash flows position Company for execution

- $6.4 million cash flow from collaborations in first quarter 2022, ending the quarter with $719.8 million in cash and cash equivalents

- First quarter 2022 net cash outflows from operations of approximately $10.4 million

- $100 million upfront payment from Sanofi collaboration signed in January 2022 was received in April, and will be reflected in cash inflows for the second quarter 2022

Further expanded Exscientia’s leadership team

- Michael Krams, M.D., was appointed as Chief Quantitative Medicine Officer, and will lead the clinical development strategy for Exscientia’s portfolio of investigational medicines

Investor Call and Webcast Information

Exscientia will host a conference call on Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at Alternatively, the live conference call can be accessed by dialling +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website.

First Quarter 2022 Financial Results

For the convenience of the reader, the Company has translated pound sterling amounts to U.S. dollars at the rate of £1.000 to $1.3152, which was the noon buying rate of the Federal Reserve Bank of New York on March 31, 2022.

Revenue: Revenue for the first quarter 2022, was $9.2 million, an increase of $2.2 million compared to the first quarter 2021, primarily due to additional revenues derived from an extension of the Company’s first collaboration with BMS in March 2022 to generate additional data including leveraging translational research capabilities for key targets under the collaboration, as well as revenue from additional targets in the second BMS collaboration.

R&D and cost of drug discovery: Due to various collaboration structures, expenditure incurred in relation to research and development activities may be recognised within one of several financial statement captions. The tables below show how these expenses are separated across the accounting categories.

Three months ended March 31, 2022 ($ millions):



Share of
JV loss


Partnered Programmes





Co-owned Programmes





Internal Pipeline and Technology Development










General and administrative expenses: G&A expenses for the three months ended March 31, 2022, were $10.3 million, or 21% of total operating expenses. For the first quarter 2022, G&A expenses increased by $6.0 million compared to the first quarter 2021, primarily associated with an increase in personnel costs.

Cash inflows: For the first quarter 2022, Exscientia received $6.4 million in cash inflows from its collaborations as compared to $0.2 million during the first quarter 2021.

Cash and cash equivalents: Cash and cash equivalents as of March 31, 2022, were $719.8 million as compared to $739.4 million as of December 31, 2021.


($ millions, except per share data, at the rate of £1.000 to $1.3152)

Three months ended March 31,






Cost of sales



Research and development expenses



General and administrative expenses



Operating expenses



Foreign exchange gains/(losses)



Other income



Operating loss



Finance income/(expense)



Share of loss on joint ventures



Loss before taxation



Income tax benefit



Loss for the period



Net loss per share




($ millions, except per share data, at the rate of £1.000 to $1.3152)

March 31, 2022

December 31, 2021

Cash and cash equivalents



Total assets



Total equity



Total liabilities



Total equity and liabilities




($ millions, except per share data, at the rate of £1.000 to $1.3152)

March 31, 2022

March 31, 2021

Net cash flows used in operating activities



Net cash flows used in investing activities



Net cash generated from financing activities



Net increase in cash and cash equivalents



About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

For more information visit us on or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its projected revenue and cash runway. Any statement describing Exscientia’s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on the Company’s business, and including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Registration Statement on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022, as amended (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at, the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Sara Sherman

Amanda Galgay

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom